Genedata Biologics 4.0 Enables Large-scale Design, Synthesis, and Testing of Bispecific Antibodies
Product News Apr 02, 2014
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced the release of Genedata Biologics™ 4.0, the latest version of its enterprise workflow support and data management solution for biologics R&D. This major new release provides novel tools for systematically designing, cloning, expressing, purifying, and testing bi- and multi-specific antibodies. Able to simultaneously co-engage with different antigen targets, these new antibody formats are currently being broadly adopted by the biopharmaceutical industry, primarily for developing the next-generation of oncology and immune system therapies. Genedata Biologics is meeting the challenges of developing these complex multi-specific antibodies by providing new tools to enable more efficient molecule design, production, and characterization.
High-Throughput Next-Generation Antibody Generation and Testing
Genedata Biologics 4.0 enables standardized processing and assessment of next-generation antibody formats (e.g. Fab-scFv, KinH, IgG-scFv, DVD-Ig, tandem-scFv-Fc), including the huge underlying combinatorial complexity of all parametric variants (e.g. linkers, V-domain order, Fc). In addition to supporting established formats, the system can be configured to work with completely novel multi-specific antibody-like molecules, new scaffolds, and proprietary engineering techniques (e.g. Fc-engineering, chimerization, humanization). Automating downstream expression, purification, and characterization processes, Genedata Biologics substantially increases throughput.
Genedata Biologics resolves major bottlenecks in high-throughput molecular biology and cloning processes. These processes are required to systematically generate and validate DNA constructs to express the desired next-generation molecules. The platform supports multi-specific engineering strategies by identifying the most successful combination of antigen binders and formats and scales up cloning and production by directly integrating with laboratory automation equipment. Genedata Biologics also automatically aggregates all assay and analytics results, facilitating decision-making on which candidate to move forward.
"The next-generation of biotherapeutics are built on bispecifics and other innovative, highly engineered large-molecules such as antibody drug conjugates. Therefore, today's biopharmas are faced with generating and testing vastly increased numbers of diverse alternative antibody molecule formats," said Dr. Othmar Pfannes, CEO of Genedata. "This new version of Genedata Biologics can handle increasingly complex and proprietary molecule types and enables the necessary throughput and automation to get new high-quality candidates into clinical development faster. This makes Genedata Biologics the workflow management platform of choice for all biologics R&D organizations."
Genedata Biologics V 4.0 is available now and shipping directly from Genedata.